FR UK Bienvenue "guest"  S'identifier  Rechercher :

dbCGE > Equipes > Equipe A05 - Virothérapie du cancer Equipes - Rechercher

Equipe A05 - Virothérapie du cancer

Responsable(s) de l'équipe : Pr Jean ROMMELAERE
Site internet : http://www.dkfz.de/de/f010/index.html
Affiliation
Thèmes de recherche

Action anti-cancéreuse des parvovirus et des vecteurs recombinants qui en dérivent.

Thèmes de recherche Cancer

Cibles parvovirales pour la virothérapie du cancer: oncolyse et immunomodulation

Mots clés
Parvovirus-Cancer-Oncolyse-Thérapie génique-Immunothérapie -
Membres de l'équipe
  • Ouvrir Marc APRAHAMIAN
  • Ouvrir Christiane DINSART
  • Ouvrir Antonio MARCHINI
  • Ouvrir Jürg NUESCH
  • Ouvrir Jean ROMMELAERE
  • Ouvrir Nathalie SALOME
Projets
Ouvrir2007 - PARVO-HDAC (porteur : Christiane MOUGIN)
Synergistic of combined Parvovirus and Sodium Butyrate treatments against human cervical cancer
Ouvrir2007 - H1PVRNAI (porteur : Antonio Marchini)
Exploring the early steps of infection of H-1 oncolytic parvovirus
Ouvrir2005 - CGE-DKFZ (porteur : Christine CLAVEL)
Deutsches Krebsforschungszentrum (DKFZ)/Cancéropôle du Grand-Est (CGE) joint research programme in Applied Tumour Virology HPV INFECTION AND CANCER
Ouvrir2005 - PNES Poumon (porteur : )
PNES Poumon
Ouvrir2005 - PNES Rein (porteur : )
PNES Rein
  • Ouvrir 2008 - ARC - Caractérisation du processus de l'hépatocarcinogenèse chez les souris mutantes TIF1alphaL2/L2 Cre-Alb et corrélation avec les mutations génétiques dans l'hépatocarcinome humain.
  • Ouvrir 2005 - HGF-BMBF-DKFZ - Projet CGE-DKFZ en virologie tumorale appliquée
  • Ouvrir 2004 - German-Israeli foundation for scientific R & D - The involvement of viral elements in the tissue tropism and pathogenicity of parvoviruses
  • Ouvrir 2003 - Deutsche Krebshilfe - Autonome Parvovirus vermittelte Tumorzelllyse-Analyse der Immunantwort beim Menschen und der Maus.
Collaborations
  • CHRISTENSEN, Jesper, Frederiksberg, Danemark
  • GALABOV, Angel, Institute of Microbiology, Sofia, Bulgarie
  • GELETNEKY, Karsten, Université de Heidelberg, Heidelberg, Allemagne
  • MOEHLER, Markus, Université de Mayence, Mayence, Allemagne
  • RAPPOLD, Gudrun, Université de Heidelberg, Heidelberg, Allemagne
  • SCHNOLZER, Martina, DKFZ, Heidelberg, Allemagne
  • SOZZANI, Silvano, Mario Negri Institute for Pharmacological Research, Milan, Italie
  • TATTERSALL, Peter, Yale University School of Medicine, New Haven, Etats-Unis
  • VANDAMME, Jo, Rega Institute, Louvain, Belgique
  • WHELAN, Maurice, Joint Research Centre, JRC, Ispra, Italie
  • XIAO, Shu-dong, Shanghai Institute of Digestive Diseases, Shanghai, Chine
Publications
  • Ouvrir Hristov G, Marttila T, Durand C, Niesler B, Rappold GA, Marchini A. SHOX triggers the lysosomal pathway of apoptosis via oxidative stress. Hum Mol Genet. 2014 Mar 15;23(6):1619-30. doi: 10.1093/hmg/ddt552. Epub 2013 Nov 1.
  • Ouvrir Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Ruffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA. Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer. J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.
  • Ouvrir Bour G, Martel F, Goffin L, Bayle B, Gangloff J, Aprahamian M, Marescaux J, Egly JM. Design and Development of a Robotized System Coupled to microCT Imaging for Intratumoral Drug Evaluation in a HCC Mouse Model. PLoS One. 2014 Sep 9;9(9):e106675. doi: 10.1371/journal.pone.0106675. eCollection 2014.
  • Ouvrir Nuesch JP, Rommelaere J. Tumor Suppressing Properties of Rodent Parvovirus NS1 Proteins and Their Derivatives. Adv Exp Med Biol. 2014;818:99-124. doi: 10.1007/978-1-4471-6458-6_5.
  • Ouvrir Beiser KU, Glaser A, Kleinschmidt K, Scholl I, Roth R, Li L, Gretz N, Mechtersheimer G, Karperien M, Marchini A, Richter W, Rappold GA. Identification of Novel SHOX Target Genes in the Developing Limb Using a Transgenic Mouse Model. PLoS One. 2014 Jun 2;9(6):e98543. doi: 10.1371/journal.pone.0098543. eCollection 2014.
  • Ouvrir Moehler M, Goepfert K, Heinrich B, Breitbach CJ, Delic M, Galle PR, Rommelaere J. Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1. Front Oncol. 2014 May 1;4:92. doi: 10.3389/fonc.2014.00092. eCollection 2014. - Review
  • Ouvrir Lavie M, Struyf S, Stroh-Dege A, Rommelaere J, Van Damme J, Dinsart C. Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. Virology. 2013 Dec;447(1-2):221-32. doi: 10.1016/j.virol.2013.09.019. Epub 2013 Oct 4.
  • Ouvrir Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M. Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy. Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.
  • Ouvrir Li J, Bonifati S, Hristov G, Marttila T, Valmary-Degano S, Stanzel S, Schnolzer M, Mougin C, Aprahamian M, Grekova SP, Raykov Z, Rommelaere J, Marchini A. Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas. EMBO Mol Med. 2013 Oct;5(10):1537-55. doi: 10.1002/emmm.201302796. Epub 2013 Sep 17.
  • Ouvrir Porwal M, Cohen S, Snoussi K, Popa-Wagner R, Anderson F, Dugot-Senant N, Wodrich H, Dinsart C, Kleinschmidt JA, Pante N, Kann M. Parvoviruses cause nuclear envelope breakdown by activating key enzymes of mitosis. PLoS Pathog. 2013 Oct;9(10):e1003671. doi: 10.1371/journal.ppat.1003671. Epub 2013 Oct 31.
  • Ouvrir Bar S, Rommelaere J, Nuesch JP. Vesicular Transport of Progeny Parvovirus Particles through ER and Golgi Regulates Maturation and Cytolysis. PLoS Pathog. 2013 Sep;9(9):e1003605. doi: 10.1371/journal.ppat.1003605. Epub 2013
  • Ouvrir Lacroix J, Schlund F, Leuchs B, Adolph K, Sturm D, Bender S, Hielscher T, Pfister SM, Witt O, Rommelaere J, Schlehofer JR, Witt H. Oncolytic effects of parvovirus H-1 in medulloblastoma are associated with repression of master regulators of early neurogenesis. Int J Cancer. 2014 Feb 1;134(3):703-16. doi: 10.1002/ijc.28386. Epub 2013 Sep 2.
  • Ouvrir Halder S, Nam HJ, Govindasamy L, Vogel M, Dinsart C, Salome N, McKenna R, Agbandje-McKenna M. Structural characterization of H-1 parvovirus: comparison of infectious virions to empty capsids. J Virol. 2013 May;87(9):5128-40. doi: 10.1128/JVI.03416-12. Epub 2013 Feb 28.
  • Ouvrir Bhat R, Rommelaere J. NK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cells. BMC Cancer. 2013 Jul 31;13:367. doi: 10.1186/1471-2407-13-367.
  • Ouvrir Raykov Z, Grekova SP, Horlein R, Leuchs B, Giese T, Giese NA, Rommelaere J, Zawatzky R, Daeffler L. TLR-9 contributes to the antiviral innate immune sensing of rodent parvoviruses MVMp and H-1PV by normal human immune cells. PLoS One. 2013;8(1):e55086. doi: 10.1371/journal.pone.0055086. Epub 2013 Jan 29.
  • Ouvrir Halder S, Nam HJ, Govindasamy L, Vogel M, Dinsart C, Salome N, McKenna R, Agbandje-McKenna M. Production, purification, crystallization and structure determination of H-1 Parvovirus. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2012 Dec 1;68(Pt 12):1571-6.
  • Ouvrir Sieben M, Schafer P, Dinsart C, Galle PR, Moehler M. Activation of the human immune system via toll-like receptors by the oncolytic parvovirus H-1. Int J Cancer. 2013 Jun 1;132(11):2548-56. doi: 10.1002/ijc.27938. Epub 2012 Nov
  • Ouvrir Grekova SP, Rommelaere J, Raykov Z. Parvoviruses-tools to fine-tune anticancer immune responses. Oncoimmunology. 2012 Nov 1;1(8):1417-1419.
  • Ouvrir Derbal-Wolfrom L, Pencreach E, Saandi T, Aprahamian M, Martin E, Greferath R, Tufa E, Choquet P, Lehn JM, Nicolau C, Duluc I, Freund JN. Increasing the oxygen load by treatment with myo-inositol trispyrophosphate reduces growth of colon cancer and modulates the intestine homeobox gene Cdx2. Oncogene. 2013 Sep 5;32(36):4313-8. doi: 10.1038/onc.2012.445. Epub 2012 Oct 8.
  • Ouvrir El-Andaloussi N, Bonifati S, Kaufmann JK, Mailly L, Daeffler L, Deryckere F, Nettelbeck DM, Rommelaere J, Marchini A. Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential. J Virol. 2012 Oct;86(19):10418-31. doi: 10.1128/JVI.00848-12. Epub 2012 Jul 11.
  • Ouvrir Wang YY, Liu J, Zheng Q, Ran ZH, Salome N, Vogel M, Rommelaere J, Xiao SD, Wang Z. Effect of the parvovirus H-1 non-structural protein NS1 on the tumorigenicity of human gastric cancer cells. J Dig Dis. 2012 Jul;13(7):366-73. doi: 10.1111/j.1751-2980.2012.00601.x.
  • Ouvrir Sanchez-Martinez C, Grueso E, Carroll M, Rommelaere J, Almendral JM. Essential role of the unordered VP2 n-terminal domain of the parvovirus MVM capsid in nuclear assembly and endosomal enlargement of the virion fivefold channel for cell entry. Virology. 2012 Oct 10;432(1):45-56. Epub 2012 Jun 23.
  • Ouvrir Dempe S, Lavie M, Struyf S, Bhat R, Verbeke H, Paschek S, Berghmans N, Geibig R, Rommelaere J, Van Damme J, Dinsart C. Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother. 2012 Nov;61(11):2113-23. doi:
  • Ouvrir Nuesch JP, Lacroix J, Marchini A, Rommelaere J. Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res. 2012 Jul 1;18(13):3516-23. doi: 10.1158/1078-0432.CCR-11-2325. - Review
  • Ouvrir Weiss N, Stroh-Dege A, Rommelaere J, Dinsart C, Salome N. An in-frame deletion in the NS protein-coding sequence of parvovirus H-1PV efficiently stimulates export and infectivity of progeny virions. J Virol. 2012 Jul;86(14):7554-64. Epub 2012 May 2.
  • Ouvrir Rappold GA, Durand C, Decker E, Marchini A, Schneider KU. New roles of SHOX as regulator of target genes. Pediatr Endocrinol Rev. 2012 May;9 Suppl 2:733-8.
  • Ouvrir Grekova SP, Raykov Z, Zawatzky R, Rommelaere J, Koch U. Activation of a glioma-specific immune response by oncolytic parvovirus Minute Virus of Mice infection. Cancer Gene Ther. 2012 Jul;19(7):468-75. doi: 10.1038/cgt.2012.20. Epub 2012 Apr
  • Ouvrir Allaume X, El-Andaloussi N, Leuchs B, Bonifati S, Kulkarni A, Marttila T, Kaufmann JK, Nettelbeck DM, Kleinschmidt J, Rommelaere J, Marchini A. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J Virol. 2012 Apr;86(7):3452-65. Epub 2012 Jan 18.
  • Ouvrir Geletneky K, Huesing J, Rommelaere J, Schlehofer JR, Leuchs B, Dahm M, Krebs O, von Knebel Doeberitz M, Huber B, Hajda J. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer. 2012 Mar 21;12:99. doi: 10.1186/1471-2407-12-99.
  • Ouvrir El-Andaloussi N, Leuchs B, Bonifati S, Rommelaere J, Marchini A. Efficient recombinant parvovirus production with the help of adenovirus-derived systems. J Vis Exp. 2012 Apr 23;(62). pii: 3518. doi: 10.3791/3518.
  • Ouvrir Morales O, Richard A, Martin N, Mrizak D, Senechal M, Miroux C, Pancre V, Rommelaere J, Caillet-Fauquet P, de Launoit Y, Delhem N. Activation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirus. PLoS One. 2012;7(2):e32197. Epub 2012 Feb 16.
  • Ouvrir Grekova SP, Aprahamian M, Daeffler L, Leuchs B, Angelova A, Giese T, Galabov A, Heller A, Giese NA, Rommelaere J, Raykov Z. Interferon gamma improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer. Cancer Biol Ther. 2011 Nov 15;12(10):888-95. Epub 2011 Nov 15.
  • Ouvrir Moehler M, Sieben M, Roth S, Springsguth F, Leuchs B, Zeidler M, Dinsart C, Rommelaere J, Galle PR. Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer. 2011 Oct 26;11:464.
  • Ouvrir Kiprianova I, Thomas N, Ayache A, Fischer M, Leuchs B, Klein M, Rommelaere J, Schlehofer JR. Regression of glioma in rat models by intranasal application of parvovirus h-1. Clin Cancer Res. 2011 Aug 15;17(16):5333-42. doi: 10.1158/1078-0432.CCR-10-3124.
  • Ouvrir Alkassar M, Gartner B, Roemer K, Graesser F, Rommelaere J, Kaestner L, Haeckel I, Graf N. The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo. J Neurooncol. 2011 Sep;104(3):715-27. Epub 2011 May 24.
  • Ouvrir Aprahamian M, Bour G, Akladios CY, Fylaktakidou K, Greferath R, Soler L, Marescaux J, Egly JM, Lehn JM, Nicolau C. Myo-InositolTrisPyroPhosphate treatment leads to HIF-1alpha suppression and eradication of early hepatoma tumors in rats. Chembiochem. 2011 Mar 21;12(5):777-83. doi: 10.1002/cbic.201000619. Epub
  • Ouvrir Akladios CY, Bour G, Balboni G, Mutter D, Marescaux J, Aprahamian M. [Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats]. Bull Cancer. 2011 Feb 1;98(2):120-32.
  • Ouvrir Grekova S, Aprahamian M, Giese N, Schmitt S, Giese T, Falk CS, Daeffler L, Cziepluch C, Rommelaere J, Raykov Z. Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent. Cancer Biol Ther. 2010 Dec 15;10(12):1280-9. Epub 2010 Dec 15.
  • Ouvrir El-Andaloussi N, Endele M, Leuchs B, Bonifati S, Kleinschmidt J, Rommelaere J, Marchini A. Novel adenovirus-based helper system to support production of recombinant parvovirus. Cancer Gene Ther. 2011 Apr;18(4):240-9. Epub 2010 Nov 19.
  • Ouvrir Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR. Therapeutic implications of the enhanced short and long-term cytotoxicity of radiation treatment followed by oncolytic parvovirus H-1 infection in high-grade glioma cells. Bioeng Bugs. 2010 Nov-Dec;1(6):429-33.
  • Ouvrir Decrion-Barthod AZ, Bosset M, Plissonnier ML, Marchini A, Nicolier M, Launay S, Pretet JL, Rommelaere J, Mougin C. Sodium butyrate with UCN-01 has marked antitumour activity against cervical cancer cells. Anticancer Res. 2010 Oct;30(10):4049-61.
  • Ouvrir Lacroix J, Leuchs B, Li J, Hristov G, Deubzer HE, Kulozik AE, Rommelaere J, Schlehofer JR, Witt O. Parvovirus H1 selectively induces cytotoxic effects on human neuroblastoma cells. Int J Cancer. 2010 Sep 1;127(5):1230-9.
  • Ouvrir Dempe S, Stroh-Dege AY, Schwarz E, Rommelaere J, Dinsart C. SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV. Int J Cancer. 2010 Jun 15;126(12):2914-27.
  • Ouvrir Hristov G, Kramer M, Li J, El-Andaloussi N, Mora R, Daeffler L, Zentgraf H, Rommelaere J, Marchini A. Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species. J Virol. 2010 Jun;84(12):5909-22. Epub 2010 Apr 7.
  • Ouvrir Bhat R, Dempe S, Dinsart C, Rommelaere J. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer. 2011 Feb 15;128(4):908-19. doi: 10.1002/ijc.25415.
  • Ouvrir Geletneky K, Kiprianova I, Ayache A, Koch R, Herrero Y Calle M, Deleu L, Sommer C, Thomas N, Rommelaere J, Schlehofer JR. Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models. Neuro Oncol. 2010 Aug;12(8):804-14. Epub 2010 Mar 18.
  • Ouvrir Rommelaere J, Geletneky K, Angelova AL, Daeffler L, Dinsart C, Kiprianova I, Schlehofer JR, Raykov Z. Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):185-95. Epub 2010 Mar 7. - Review
  • Ouvrir Grekova S, Zawatzky R, Horlein R, Cziepluch C, Mincberg M, Davis C, Rommelaere J, Daeffler L. Activation of an antiviral response in normal but not transformed mouse cells: a new determinant of minute virus of mice oncotropism. J Virol. 2010 Jan;84(1):516-31. Epub .
  • Ouvrir Geletneky K, Hartkopf AD, Krempien R, Rommelaere J, Schlehofer JR. Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection. J Biomed Biotechnol. 2010;2010:350748. Epub 2010 Mar 7.
  • Ouvrir Ignat M, Aprahamian M, Lindner V, Altmeyer A, Perretta S, Dallemagne B, Mutter D, Marescaux J. Feasibility and Reliability of Pancreatic Cancer Staging Using Fiberoptic Confocal Fluorescence Microscopy in Rats Gastroenterology. 2009 Nov;137(5):1584-92.e1. Epub 2009 Jul 24.
  • Ouvrir Angelova AL, Aprahamian M, Balboni G, Delecluse HJ, Feederle R, Kiprianova I, Grekova SP, Galabov AS, Witzens-Harig M, Ho AD, Rommelaere J, Raykov Z. Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: In vitro and in vivo studies. Mol Ther. 2009 Jul;17(7):1164-72. Epub 2009 Apr 14.
  • Ouvrir Nuesch JP, Bar S, Lachmann S, Rommelaere J. Ezrin-radixin-moesin family proteins are involved in parvovirus replication and spreading. J Virol. 2009 Jun;83(11):5854-63. Epub 2009 Mar 25.
  • Ouvrir Struyf S, Proost P, Vandercappellen J, Dempe S, Noyens B, Nelissen S, Gouwy M, Locati M, Opdenakker G, Dinsart C, Van Damme J. Synergistic up-regulation of MCP-2/CCL8 activity is counteracted by chemokine cleavage, limiting its inflammatory and anti-tumoral effects. Eur J Immunol. 2009 Mar;39(3):843-57.
  • Ouvrir Enderlin M, Kleinmann EV, Struyf S, Buracchi C, Vecchi A, Kinscherf R, Kiessling F, Paschek S, Sozzani S, Rommelaere J, Cornelis JJ, Van Damme J, Dinsart C. TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther. 2009 Feb;16(2):149-60. Epub 2008 Aug 1.
  • Ouvrir Angelova AL, Aprahamian M, Grekova SP, Hajri A, Leuchs B, Giese NA, Dinsart C, Herrmann A, Balboni G, Rommelaere J, Raykov Z. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin Cancer Res. 2009 Jan 15;15(2):511-9.
  • Ouvrir Raykov Z, Georgieva PB, Angelova A, Galabov AS, Rommelaere J. Anticancer effects of an oncolytic parvovirus combined with non-conventional therapeutics on pancreatic carcinoma cell lines. Acta Virol. 2009;53(1):57-60.
  • Ouvrir Mancini A, Borrelli A, Schiattarella A, Aloj L, Aurilio M, Morelli F, Pica A, Occhiello A, Lorizio R, Mancini R, Sica A, Mazzarella L, Sica F, Grieco P, Novellino E, Pagnozzi D, Pucci P, Rommelaere J. Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent. Int J Cancer. 2008 Dec 1;123(11):2684-95.
  • Ouvrir Nuesch JP, Bar S, Rommelaere J. Viral proteins killing tumor cells: new weapons in the fight against cancer. Cancer Biol Ther. 2008 Sep;7(9):1374-6. Epub 2008 Sep 5. - Comment
  • Ouvrir Sieben M, Herzer K, Zeidler M, Heinrichs V, Leuchs B, Schuler M, Cornelis JJ, Galle PR, Rommelaere J, Moehler M. Killing of p53-deficient hepatoma cells by parvovirus H-1 and chemotherapeutics requires promyelocytic leukemia protein. World J Gastroenterol. 2008 Jun 28;14(24):3819-28.
  • Ouvrir Raykov Z, Grekova S, Leuchs B, Aprahamian M, Rommelaere J. Arming parvoviruses with CpG motifs to improve their oncosuppressive capacity. Int J Cancer. 2008 Jun 15;122(12):2880-4.
  • Ouvrir Engelsma D, Valle N, Fish A, Salome N, Almendral JM, Fornerod M. A supraphysiological nuclear export signal is required for parvovirus nuclear export. Mol Biol Cell. 2008 Jun;19(6):2544-52. Epub 2008 Apr 2.
  • Ouvrir Raykov Z, Rommelaere J. Potential of tumour cells for delivering oncolytic viruses. Gene Ther. 2008 May;15(10):704-10. Epub 2008 Mar 20. - Review
  • Ouvrir Kruger L, Eskerski H, Dinsart C, Cornelis J, Rommelaere J, Haberkorn U, Kleinschmidt JA. Augmented transgene expression in transformed cells using a parvoviral hybrid vector. Cancer Gene Ther. 2008 Apr;15(4):252-67. Epub 2008 Jan 18.
  • Ouvrir Lachmann S, Bar S, Rommelaere J, Nuesch JP. Parvovirus interference with intracellular signalling: mechanism of PKCeta activation in MVM-infected A9 fibroblasts. Cell Microbiol. 2008 Mar;10(3):755-69. Epub 2007 Nov 27.
  • Ouvrir Wack S, Rejiba S, Parmentier C, Aprahamian M, Hajri A. Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther. 2008 Feb;16(2):252-60. Epub 2007 Nov 6.
  • Ouvrir Bar S, Daeffler L, Rommelaere J, Nuesch JP. Vesicular egress of non-enveloped lytic parvoviruses depends on gelsolin functioning. PLoS Pathog. 2008 Aug 15;4(8):e1000126.
  • Ouvrir Marchini A, Hacker B, Marttila T, Hesse V, Emons J, Weiss B, Karperien M, Rappold G. BNP is a transcriptional target of the short stature homeobox gene SHOX. Hum Mol Genet. 2007 Dec 15;16(24):3081-7. Epub 2007 Sep 19.
  • Ouvrir Nuesch JP, Rommelaere J. A viral adaptor protein modulating casein kinase II activity induces cytopathic effects in permissive cells. Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12482-7. Epub 2007 Jul 16.
  • Ouvrir Rejiba S, Wack S, Aprahamian M, Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 2007 Jul;98(7):1128-36. Epub 2007 May 8.
  • Ouvrir Raykov Z, Grekova S, Galabov AS, Balboni G, Koch U, Aprahamian M, Rommelaere J. Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model Oncol Rep. 2007 Jun;17(6):1493-9.
  • Ouvrir Tanaka K, Mutter D, Inoue H, Lindner V, Bouras G, Forgione A, Leroy J, Aprahamian M, Marescaux J. In vivo evaluation of a new composite mesh (10% polypropylene/90% poly-L-lactic acid) for hernia repair. J Mater Sci Mater Med. 2007 Jun;18(6):991-9. Epub 2007 Jan 23.
  • Ouvrir Deharvengt S, Rejiba S, Wack S, Aprahamian M, Hajri A. Efficient electrogene therapy for pancreatic adenocarcinoma treatment using the bacterial purine nucleoside phosphorylase suicide gene with fludarabine Int J Oncol. 2007 Jun;30(6):1397-406.
  • Ouvrir Marchini A, Rappold G, Schneider KU. SHOX at a glance: from gene to protein. Arch Physiol Biochem. 2007 Jun;113(3):116-23. - Review
  • Ouvrir Di Piazza M, Mader C, Geletneky K, Herrero Y Calle M, Weber E, Schlehofer J, Deleu L, Rommelaere J. Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells. J Virol. 2007 Apr;81(8):4186-98. Epub 2007 Feb 7.
  • Ouvrir Wetzel K, Struyf S, Van Damme J, Kayser T, Vecchi A, Sozzani S, Rommelaere J, Cornelis JJ, Dinsart C. MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer. 2007 Mar 15;120(6):1364-71.
  • Ouvrir Ayadi A, Bour G, Aprahamian M, Bayle B, Graebling P, Gangloff J, Soler L, Egly JM, Marescaux J. Fully automated image-guided needle insertion: application to small animal biopsies. Conf Proc IEEE Eng Med Biol Soc. 2007;2007:194-7.
  • Ouvrir Lang SI, Giese NA, Rommelaere J, Dinsart C, Cornelis JJ. Humoral immune responses against minute virus of mice vectors. J Gene Med. 2006 Sep;8(9):1141-50.
  • Ouvrir Abschuetz A, Kehl T, Geibig R, Leuchs B, Rommelaere J, Regnier-Vigouroux A. Oncolytic murine autonomous parvovirus, a candidate vector for glioma gene therapy, is innocuous to normal and immunocompetent mouse glial cells. Cell Tissue Res. 2006 Sep;325(3):423-36. Epub 2006 May 3.
  • Ouvrir Mancini A, Borrelli A, Schiattarella A, Fasano S, Occhiello A, Pica A, Sehr P, Tommasino M, Nuesch JP, Rommelaere J. Tumor suppressive activity of a variant isoform of manganese superoxide dismutase released by a human liposarcoma cell line. Int J Cancer. 2006 Aug 15;119(4):932-43.
  • Ouvrir Winnefeld M, Grewenig A, Schnolzer M, Spring H, Knoch TA, Gan EC, Rommelaere J, Cziepluch C. Human SGT interacts with Bag-6/Bat-3/Scythe and cells with reduced levels of either protein display persistence of few misaligned chromosomes and mitotic arrest. Exp Cell Res. 2006 Aug 1;312(13):2500-14. Epub 2006 May 13.
  • Ouvrir Nuesch JP, Rommelaere J. NS1 interaction with CKII alpha: novel protein complex mediating parvovirus-induced cytotoxicity. J Virol. 2006 May;80(10):4729-39.
  • Ouvrir Marchini A, Daeffler L, Marttila T, Schneider KU, Blaschke RJ, Schnolzer M, Rommelaere J, Rappold G. Phosphorylation on Ser106 modulates the cellular functions of the SHOX homeodomain protein. J Mol Biol. 2006 Jan 20;355(3):590-603. Epub 2005 Nov 21.
  • Ouvrir Geletneky K, Herrero Y Calle M, Rommelaere J, Schlehofer JR. Oncolytic potential of rodent parvoviruses for cancer therapy in humans: a brief review. J Vet Med B Infect Dis Vet Public Health. 2005 Sep-Oct;52(7-8):327-30. - Review
  • Ouvrir Moehler MH, Zeidler M, Wilsberg V, Cornelis JJ, Woelfel T, Rommelaere J, Galle PR, Heike M. Parvovirus H-1-induced tumor cell death enhances human immune response in vitro via increased phagocytosis, maturation, and cross-presentation by dendritic cells. Hum Gene Ther. 2005 Aug;16(8):996-1005.
  • Ouvrir Schneider KU, Marchini A, Sabherwal N, Roth R, Niesler B, Marttila T, Blaschke RJ, Lawson M, Dumic M, Rappold G. Alteration of DNA binding, dimerization, and nuclear translocation of SHOX homeodomain mutations identified in idiopathic short stature and Leri-Weill dyschondrosteosis. Hum Mutat. 2005 Jul;26(1):44-52.
  • Ouvrir Deharvengt S, Wack S, Aprahamian M, Hajri A. Transcriptional tumor-selective promoter targeting of E. coli purine nucleoside phosphorylase for pancreatic cancer suicide gene therapy. J Gene Med. 2005 May;7(5):672-80.
  • Ouvrir Raykov Z, Savelyeva L, Balboni G, Giese T, Rommelaere J, Giese NA. B1 lymphocytes and myeloid dendritic cells in lymphoid organs are preferential extratumoral sites of parvovirus minute virus of mice prototype strain expression. J Virol. 2005 Mar;79(6):3517-24.
  • Ouvrir Li J, Werner E, Hergenhahn M, Poirey R, Luo Z, Rommelaere J, Jauniaux JC. Expression profiling of human hepatoma cells reveals global repression of genes involved in cell proliferation, growth, and apoptosis upon infection with parvovirus H-1. J Virol. 2005 Feb;79(4):2274-86.
  • Ouvrir Nuesch JP, Lachmann S, Rommelaere J. Selective alterations of the host cell architecture upon infection with parvovirus minute virus of mice. Virology. 2005 Jan 5;331(1):159-74.
  • Ouvrir Liu J, Ran ZH, Xiao SD, Rommelaere J. Changes in gene expression profiles induced by parvovirus H-1 in human gastric cancer cells. Chin J Dig Dis. 2005;6(2):72-81.
  • Ouvrir Lang SI, Boelz S, Stroh-Dege AY, Rommelaere J, Dinsart C, Cornelis JJ. The infectivity and lytic activity of minute virus of mice wild-type and derived vector particles are strikingly different. J Virol. 2005 Jan;79(1):289-98.
  • Ouvrir Herrero Y Calle M, Cornelis JJ, Herold-Mende C, Rommelaere J, Schlehofer JR, Geletneky K. Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing. Int J Cancer. 2004 Mar;109(1):76-84.
  • Ouvrir Daeffler L, Horlein R, Rommelaere J, Nuesch JP. Modulation of minute virus of mice cytotoxic activities through site-directed mutagenesis within the NS coding region. J Virol. 2003 Dec;77(23):12466-78.
  • Ouvrir Malerba M, Daeffler L, Rommelaere J, Iggo RD. Replicating parvoviruses that target colon cancer cells. J Virol. 2003 Jun;77(12):6683-91.
  • Ouvrir Eichwald V, Daeffler L, Klein M, Rommelaere J, Salome N. The NS2 proteins of parvovirus minute virus of mice are required for efficient nuclear egress of progeny virions in mouse cells. J Virol. 2002 Oct;76(20):10307-19.
Brevets
Ouvrir
Application 01 116 856.4 (Eur), 10/483, 234 (USA).
Compositions comprising a parvovirus VP1 variant and a parvovirus NS1 protein for induction of cytolysis.
Daeffler, L., Nüesch, J.P.F. and Rommelaere, J.
Ouvrir
Application 09/807,579 (USA).
Parvovirus vectors and their use.
Rommelaere, J., Cornelis, J., Dinsart, C., Tattersall, P., Cotmore, S. and d'Abramo, A.
Ouvrir
Application 10/426,709 (USA).
Use of parvovirus for brain tumor therapy.
Rommelaere, J., Cornelis, J., Dinsart, C., Schlehofer, J.R., Geletneky, K. and Herrero y Calle, M.
Ouvrir
Application 60/789, 600 (USA).
Cell elimination through inactivation of Bag6/Bat3/Scythe or prevention of the interaction of this protein with hSGT.
Cziepluch, C., Winnefeld , M. and Rommelaere, J.
Ouvrir
Applications 04 729 841.9 (Eur), 11/262,356 (USA).
Fusion polypeptide suitable as a cytotoxin.
Nüesch, J.P.F. and Rommelaere, J.
Ouvrir
Applications 04 764 162.6 (Eur), x (USA).
Method to inhibit the propagation of an undesired cell population.
Cziepluch, C., Rommelaere, J. and Winnefeld, M.
Ouvrir
Applications 99 115 161.4 (Eur).
Parvovirus NS1 variants.
Nüesch, J.P.F. and Rommelaere, J.